Impinj to Announce Second-Quarter 2026 Financial Results
SEATTLE--(BUSINESS WIRE)--Impinj to Announce Second-Quarter 2026 Financial Results.
PI - Impinj, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$180.00
DETAILS
HIGH:
$220.00
LOW:
$144.00
MEDIAN:
$175.00
CONSENSUS:
$180.00
UPSIDE:
24.65%
Stock News
Director Sells 33,000 Impinj Shares Worth $4.6 Million
33,412 shares were sold indirectly on June 4, 2026, with an estimated transaction value of ~$4.57 million based on the reported price of $136.84 per share. This sale represented 3.63% of Sylebra Capital LLC's indirect holdings in Impinj, reducing total indirect ownership from 921,467 to 888,055 shares.
Director Sells 45,000 Impinj Shares Worth $6.4 Million
45,037 shares were indirectly sold for a total transaction value of ~$6.4 million, based on a weighted average price of $141.87 per share during June 2–3, 2026. The sale represented 4.66% of Sylebra Capital LLC's indirect holdings, reducing indirect ownership from 967,000 to 921,467 shares; direct holdings remained at zero.
Intel vs. Impinj: Which Technology Stock Is a Better Buy in 2026?
Intel is aggressively expanding its foundry business and AI accelerator offerings to diversify beyond traditional PC and data center chips. Impinj maintains a specialized lead in RAIN RFID technology, though its revenue remains highly concentrated among a small number of partners.
Insiders Are Selling These 3 Stocks—Should Investors Be Concerned?
Insider sales are hitting two massive stocks in industrials and retail, as well as a small-cap chip stock. Across these names, insiders are sending bearish signals, but their severity differs meaningfully.
New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myel
New TALVEYÂ (talquetamab-tgvs) plus DARZALEX FASPROÂ (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combi
Large Impinj Investor Trims Position by $11.3 Million
Impinj connects physical items to the digital world with advanced RFID solutions; a key insider recently reduced their indirect holdings.
Imagion Biosystems' IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
[url="]Imagion Biosystems, Ltd. (ASX: IBX)[/url] has announced that the US Food and Drug Administration (FDA) completed its review of the company's investigati
Impinj (PI) Just Reclaimed the 200-Day Moving Average
After reaching an important support level, Impinj (PI) could be a good stock pick from a technical perspective. PI surpassed resistance at the 200-day moving average, suggesting a long-term bullish trend.
Impinj to Participate in Evercore Global TMT Conference
SEATTLE--(BUSINESS WIRE)--Impinj to Participate in Evercore Global TMT Conference.
Impinj (PI) Just Flashed Golden Cross Signal: Do You Buy?
From a technical perspective, Impinj (PI) is looking like an interesting pick, as it just reached a key level of support. PI recently overtook the 20-day moving average, and this suggests a short-term bullish trend.
Is Impinj Inc (PI) Overvalued After 6.8% Rally? GF Value Says Overvalued
On May 22, 2026, Impinj Inc (PI) shares rose 6.8%, closing at $149.76. This positive movement comes amid a 52-week range that has seen a high of $247.06 and a l
Impinj Inc (PI) Stock Down 4.7% but Still Overvalued -- GF Score: 73/100
On May 19, 2026, Impinj Inc (PI) shares fell 4.7% today, bringing the current price to $132.74. The stock has experienced a 52-week range from a low of $87.36 t
This Beaten-Down Chip Stock Just Did Something It Hasn't Done in a Year. Time to Buy?
The catalyst lifted the chip stock to a 27% gain in the last two weeks.
How Impinj Stock Jumped 20.5% Today
Impinj posted falling profits but still beat expectations. Here's why investors celebrated the report.
This Chip Maker's Stock Is Soaring After Earnings. Analysts See 20% More Upside.
Chip maker Impinj is surging after beating earnings estimates and isuing better-than-expected second-quarter guidance.
Impinj, Inc. (PI) Q1 2026 Earnings Call Transcript
Impinj, Inc. (PI) Q1 2026 Earnings Call Transcript
Impinj (PI) Tops Q1 Earnings and Revenue Estimates
Impinj (PI) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.21 per share a year ago.
Impinj Reports First Quarter 2026 Financial Results
SEATTLE--(BUSINESS WIRE)--Impinj Reports First Quarter 2026 Financial Results.
Impinj Inc (PI) Shares Fall 3.8% -- What GF Score of 80 Tells Investors
On April 10, 2026, Impinj Inc (PI) shares fell 3.8% to a current price of $101.54. The stock has fluctuated between a 52-week high of $247.06 and a low of $62.9
Price Targets
Impinj price target raised to $176 from $169 at Barclays
$176.00
(was $144.92)
Barclays
Impinj price target raised to $144 from $112 at Evercore ISI
$144.00
(was $142.28)
Mark Lipacis
·
Evercore ISI
Impinj price target raised to $175 from $155 at UBS
$175.00
(was $120.04)
UBS
Impinj price target lowered to $155 from $190 at UBS
$155.00
(was $153.83)
UBS
Impinj price target lowered to $200 from $255 at Susquehanna
$200.00
(was $110.92)
Christopher Rolland
·
Susquehanna
Impinj price target lowered to $175 from $255 at Needham
$175.00
(was $153.83)
Needham
Impinj price target lowered to $170 from $246 at Cantor Fitzgerald
$170.00
(was $153.83)
Troy Jensen
·
Cantor Fitzgerald
Impinj downgraded to In Line from Outperform at Evercore ISI
$112.00
(was $153.83)
Mark Lipacis
·
Evercore ISI
Impinj price target lowered to $175 from $211 at Barclays
$175.00
(was $153.83)
Barclays
Impinj price target lowered to $220 from $235 at Roth Capital
$220.00
(was $153.83)
Roth Capital
Impinj price target lowered to $190 from $200 at UBS
$190.00
(was $162.13)
UBS
Impinj price target raised to $211 from $200 at Barclays
$211.00
(was $175.55)
Barclays
Impinj price target raised to $255 from $235 at Susquehanna
$255.00
(was $218.80)
Susquehanna
Impinj price target raised to $255 from $195 at Needham
$255.00
(was $241.91)
James Ricchiuti
·
Needham
Impinj price target raised to $235 from $165 at Roth Capital
$235.00
(was $241.91)
Scott Searle
·
Roth Capital
Impinj price target raised to $230 from $180 at Piper Sandler
$230.00
(was $202.08)
Piper Sandler
Impinj price target raised to $235 from $180 at Susquehanna
$235.00
(was $200.72)
Susquehanna
Impinj initiated with an Overweight at Barclays
$200.00
(was $192.97)
Barclays
Impinj Inc (PI) PT Raised to $251 at Lake Street Capital Markets
$251.00
(was $203.82)
Troy Jensen
·
Loop Capital Markets
Impinj Inc (PI) PT Raised to $245 at Needham
$245.00
(was $196.40)
James Ricchiuti
·
Needham